BBIO
Price
$50.05
Change
+$1.05 (+2.14%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
9.37B
34 days until earnings call
ENLV
Price
$1.02
Change
-$0.01 (-0.97%)
Updated
Sep 26, 04:56 PM (EDT)
Capitalization
24.57M
66 days until earnings call
Interact to see
Advertisement

BBIO vs ENLV

Header iconBBIO vs ENLV Comparison
Open Charts BBIO vs ENLVBanner chart's image
BridgeBio Pharma
Price$50.05
Change+$1.05 (+2.14%)
Volume$28.64K
Capitalization9.37B
Enlivex Therapeutics
Price$1.02
Change-$0.01 (-0.97%)
Volume$100
Capitalization24.57M
BBIO vs ENLV Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
BBIO vs. ENLV commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a StrongBuy and ENLV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (BBIO: $50.05 vs. ENLV: $1.02)
Brand notoriety: BBIO and ENLV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBIO: 26% vs. ENLV: 14%
Market capitalization -- BBIO: $9.37B vs. ENLV: $24.57M
BBIO [@Biotechnology] is valued at $9.37B. ENLV’s [@Biotechnology] market capitalization is $24.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBIO’s FA Score shows that 1 FA rating(s) are green whileENLV’s FA Score has 1 green FA rating(s).

  • BBIO’s FA Score: 1 green, 4 red.
  • ENLV’s FA Score: 1 green, 4 red.
According to our system of comparison, BBIO is a better buy in the long-term than ENLV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBIO’s TA Score shows that 4 TA indicator(s) are bullish while ENLV’s TA Score has 2 bullish TA indicator(s).

  • BBIO’s TA Score: 4 bullish, 4 bearish.
  • ENLV’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, BBIO is a better buy in the short-term than ENLV.

Price Growth

BBIO (@Biotechnology) experienced а -4.43% price change this week, while ENLV (@Biotechnology) price change was -1.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

BBIO is expected to report earnings on Oct 30, 2025.

ENLV is expected to report earnings on Dec 01, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BBIO($9.37B) has a higher market cap than ENLV($24.6M). BBIO YTD gains are higher at: 78.571 vs. ENLV (-11.966). ENLV has higher annual earnings (EBITDA): -14.21M vs. BBIO (-643.59M). BBIO has more cash in the bank: 757M vs. ENLV (19.5M). ENLV has less debt than BBIO: ENLV (480K) vs BBIO (1.86B). BBIO has higher revenues than ENLV: BBIO (236M) vs ENLV (0).
BBIOENLVBBIO / ENLV
Capitalization9.37B24.6M38,077%
EBITDA-643.59M-14.21M4,531%
Gain YTD78.571-11.966-657%
P/E RatioN/AN/A-
Revenue236M0-
Total Cash757M19.5M3,882%
Total Debt1.86B480K387,083%
FUNDAMENTALS RATINGS
BBIO vs ENLV: Fundamental Ratings
BBIO
ENLV
OUTLOOK RATING
1..100
5772
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
17
Undervalued
PROFIT vs RISK RATING
1..100
76100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4063
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (4) in the null industry is in the same range as ENLV (17) in the Medical Specialties industry. This means that BBIO’s stock grew similarly to ENLV’s over the last 12 months.

BBIO's Profit vs Risk Rating (76) in the null industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that BBIO’s stock grew similarly to ENLV’s over the last 12 months.

ENLV's SMR Rating (98) in the Medical Specialties industry is in the same range as BBIO (100) in the null industry. This means that ENLV’s stock grew similarly to BBIO’s over the last 12 months.

BBIO's Price Growth Rating (40) in the null industry is in the same range as ENLV (63) in the Medical Specialties industry. This means that BBIO’s stock grew similarly to ENLV’s over the last 12 months.

BBIO's P/E Growth Rating (100) in the null industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that BBIO’s stock grew similarly to ENLV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BBIOENLV
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 25 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RUSHB58.23-0.19
-0.33%
Rush Enterprises
MFC30.67-0.30
-0.97%
Manulife Financial Corp
LOMA7.73-0.23
-2.89%
Loma Negra Compania Industrial Argentina Sociedad Anonima
GFAI1.13-0.04
-3.42%
Guardforce AI Co Limited
BTCS4.52-0.33
-6.80%
BTCS

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with XENE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
-3.26%
XENE - BBIO
44%
Loosely correlated
-0.19%
IRON - BBIO
43%
Loosely correlated
+0.18%
RLAY - BBIO
41%
Loosely correlated
-3.10%
ALNY - BBIO
41%
Loosely correlated
-1.92%
ROIV - BBIO
41%
Loosely correlated
+1.77%
More

ENLV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENLV has been loosely correlated with APVO. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ENLV jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENLV
1D Price
Change %
ENLV100%
-1.44%
APVO - ENLV
36%
Loosely correlated
-10.11%
FENC - ENLV
26%
Poorly correlated
+3.57%
OCUL - ENLV
24%
Poorly correlated
-2.55%
BBIO - ENLV
24%
Poorly correlated
-3.26%
KZIA - ENLV
24%
Poorly correlated
-6.98%
More